NCT00111670View on ClinicalTrials.gov

A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL

Enrollment

291

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions

Diabetes Mellitus Type 2

Interventions

DRUG

DPP-IV Inhibitor

Escalating doses po bid or qd

DRUG

Placebo

po bid or qd

Trial Locations (40)

1002

Riga

1233

Sofia

1606

Sofia

5001

Ogre

7002

Rousse

14000

Mexico City

18974

Warminster

20745

Oxon Hill

21921

Elkton

23249

Richmond

23451

Virginia Beach

30513

Blue Ridge

31238

Chihuahua City

33013

Hialeah

33029

Pembroke Pines

33765

Clearwater

42086

Pachuca

44340

Guadalajara

44650

Guadalajara

45224

Cincinnati

48098

Troy

50406

Tartu

51014

Tartu

60504

Aurora

64460

Monterrey

75246

Dallas

78229

San Antonio

79707

Midland

89048

Pahrump

92304

Klaipėda

93901

Salinas

97239

Portland

100163

Ploieşti

400006

Cluj-Napoca

540011

Târgu Mureş

755-1000

San José

08661

Vilnius

06726

Mexico City

00716

Ponce

020475

Bucharest

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT00111670 - A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter